Targeting IL-33 reprograms the tumor microenvironment and potentiates antitumor response to anti-PD-...
Targeting IL-33 reprograms the tumor microenvironment and potentiates antitumor response to anti-PD-L1 immunotherapy
About this item
Full title
Author / Creator
Nan, Yanyang , Bai, Yu , Hu, Xiaozhi , Zhou, Kaicheng , Wu, Tao , Zhu, An , Li, Mengyang , Dou, Zihan , Cao, Zhonglian , Zhang, Xumeng , Xu, Shuwen , Zhang, Yuanzhen , Lin, Jun , Zeng, Xian , Fan, Jiajun , Zhang, Xuyao , Wang, Xuebin and Ju, Dianwen
Publisher
England: BMJ Publishing Group Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BMJ Publishing Group Ltd
Subjects
More information
Scope and Contents
Contents
BackgroundThe main challenge against patients with cancer to derive benefits from immune checkpoint inhibitors targeting PD-1/PD-L1 appears to be the immunosuppressive tumor microenvironment (TME), in which IL-33/ST2 signal fulfills critical functions. However, whether IL-33 limits the therapeutic efficacy of anti-PD-L1 remains uncertain.MethodsMol...
Alternative Titles
Full title
Targeting IL-33 reprograms the tumor microenvironment and potentiates antitumor response to anti-PD-L1 immunotherapy
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_638af0fc590f47d4ba79bf0e0c80b015
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_638af0fc590f47d4ba79bf0e0c80b015
Other Identifiers
ISSN
2051-1426
E-ISSN
2051-1426
DOI
10.1136/jitc-2024-009236
